In this article, we would discuss the following trends in the Iraqi pharmaceutical market:
- Growing Demand for Chronic Disease Treatments: We would highlight the fact that the prevalence of chronic diseases such as diabetes, hypertension, and cancer is increasing in Iraq, which is driving demand for specialized treatments.
- Increasing Healthcare Spending: We would discuss how the Iraqi government has increased its healthcare spending in recent years, which is creating opportunities for international healthcare companies to enter the market.
- A Shift Towards Generic Medicines: We would highlight the fact that there is a growing trend in Iraq towards the use of generic medicines, which is creating opportunities for companies that specialize in the production of generic drugs.
- Greater Investment in Healthcare Infrastructure: We would discuss how the Iraqi government is investing in the development of healthcare infrastructure, which is creating opportunities for companies that provide medical equipment and supplies.
- Favorable Regulatory Environment: We would highlight the fact that the Iraqi government has taken steps to improve the regulatory environment for pharmaceutical companies, which is making it easier for international companies to enter the market.
Overall, this article would provide international healthcare companies with a clear understanding of the opportunities and trends in the Iraqi pharmaceutical market, and would position Ekleel as a trusted partner for companies looking to enter this growing market.
The first trend driving growth in the Iraqi pharmaceutical market is the growing demand for chronic disease treatments.
According to the World Health Organization (WHO), non-communicable diseases (NCDs) are responsible for over 70% of all deaths in Iraq. The most common NCDs in the country are cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases.
As the prevalence of NCDs continues to rise in Iraq, there is a growing demand for specialized treatments. For example, the demand for insulin to treat diabetes has been increasing rapidly in recent years, with some estimates suggesting that the market for insulin in Iraq could grow to be worth over $200 million by 2024.
International pharmaceutical companies that specialize in the development and production of treatments for chronic diseases can therefore find significant opportunities in the Iraqi market. By partnering with a trusted distributor like Ekleel, these companies can gain access to this growing market and help meet the needs of Iraqi patients who are currently underserved.
Overall, the demand for chronic disease treatments is one of the key drivers of growth in the Iraqi pharmaceutical market, and is a trend that international healthcare companies looking to export products to Iraq should be aware of.